Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

TARSILA Real-World Evidence-studie (TARSILA)

2. november 2026 oppdatert av: Maicon Falavigna, Inova Medical

Reell verdenseffektivitet av mødres RSVpreF-vaksinering mot RSV-assosiert akutt luftveissykdom hos spedbarn i Brasil (TARSILA-studien): en multicentrisk, prospektiv, test-negativ, kasus-kontroll-studie

The overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants. To achieve this, two multicenter, prospective, test-negative case-control studies will be conducted among infants with ARI: the TARSILA Inpatient Study, evaluating hospitalized infants and the TARSILA Outpatient Study, evaluating infants managed in outpatient settings.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Tarsila comprises two multicenter, prospective, case-control studies using a test-negative design in Southern Brazil (states of Rio Grande do Sul, Santa Catarina, and Paraná). The Tarsila Inpatient study will enroll infants hospitalized due to acute respiratory illness and will be conducted at referral hospitals. The Tarsila Outpatient study will enroll infants with acute respiratory illness managed in outpatient settings and will be conducted at outpatient healthcare facilities. Both studies are aligned with the nationwide introduction of maternal RSVpreF vaccination in December 2025, with enrollment occurring from April, 2026 to September, 2028. In both studies, the same clinical case definition will be applied to cases and controls. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) for RSV will be prospectively performed to classify case infants (RT-qPCR positive for RSV) and control infants (RT-qPCR negative for RSV). Maternal RSVpreF vaccination status and potential confounders will be assessed through structured interviews and review of medical records.

Studietype

Observasjonsmessig

Registrering (Antatt)

5000

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Paraná
      • Cascavel, Paraná, Brasil, 85818-130
        • Rekruttering
        • Unidade de Pronto Atendimento Veneza
        • Ta kontakt med:
      • Curitiba, Paraná, Brasil, 80060-900
        • Rekruttering
        • Complexo do Hospital de Clínicas da Universidade Federal do Paraná
        • Ta kontakt med:
        • Hovedetterforsker:
          • Cristina de Oliveira Rodrigues
      • Curitiba, Paraná, Brasil, 80240-031
        • Rekruttering
        • Hospital Infantil Pequeno Príncipe
        • Ta kontakt med:
        • Hovedetterforsker:
          • Heloisa Ihle Garcia Giamberardino
      • Marechal Cândido Rondon, Paraná, Brasil, 85960-000
        • Rekruttering
        • Unidade de Pronto Atendimento 24 Horas Dr. Edgar Netzel
        • Ta kontakt med:
      • Palotina, Paraná, Brasil, 85950-000
        • Rekruttering
        • Unidade de Saúde Central de Palotina
        • Ta kontakt med:
      • Toledo, Paraná, Brasil, 85902-480
        • Rekruttering
        • Unidade de Pronto Atendimento II de Toledo
        • Ta kontakt med:
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 91350-200
        • Rekruttering
        • Hospital Nossa Senhora da Conceição
        • Ta kontakt med:
        • Hovedetterforsker:
          • Fernanda H Varela
      • Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
        • Rekruttering
        • Hospital de Clínicas de Porto Alegre
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ricardo Becker Feijó

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

Ikke eldre enn 11 måneder (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Infants with acute respiratory illness (ARI)

Beskrivelse

Tarsila Inpatient Study

Inclusion Criteria

  • Infant born in Brazil.
  • Mother resident in Brazil during the related pregnancy.
  • Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
  • Infant ≤360 days of age at time of RSV specimen collection.
  • Infant born at ≥37 weeks of gestational age.
  • Infant hospital admission for at least 24 hours with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Exclusion Criteria:

  • Maternal or infant receipt of any other licensed or investigational RSV preventive product.
  • Infant receipt of blood transfusion or other blood products containing antibodies since birth.
  • Infant previously enrolled in this study.
  • Lack of informed consent from the mother or the infant's legal guardian.
  • Absent or inconclusive RT-qPCR result for RSV.
  • Birth to a mother whose RSVpreF vaccination status could not be confirmed.

Tarsila Outpatient Study

Inclusion Criteria:

  • Infant born in Brazil.
  • Mother resident in Brazil during the related pregnancy.
  • Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
  • Infant ≤360 days of age at time of RSV specimen collection.
  • Infant born at ≥37 weeks of gestational age.
  • Infant presentation to an outpatient healthcare facility with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Exclusion Criteria:

  • Mother or infant receipt of any other licensed or investigational RSV preventive product.
  • Infant receipt of blood transfusion or other blood products containing antibodies since birth.
  • Lack of informed consent from the mother or the infant's legal guardian.
  • Absent or inconclusive RT-qPCR result for RSV.
  • Birth to a mother whose RSVpreF vaccination status could not be confirmed.
  • Enrollment in the study within the previous 30 days. If the interval exceeds 30 days, infants will be excluded if any previous episode tested positive for RSV.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: CASE_CONTROL
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Cases

Infants with a positive respiratory syncytial virus result on a nasal swab specimen

For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery.

Controls

Infants with a negative respiratory syncytial virus result on a nasal swab specimen

For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Lower respiratory Tract Disease (LRTD) Hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tidsramme: Hospitalization occurring ≤180 days after birth

Hospitalization due to RT-qPCR-confirmed RSV-positive lower respiratory tract disease, defined as cough or difficulty breathing, symptom onset within the preceding 10 days, and at least one of the following: tachypnea (respiratory rate ≥60 breaths/min for infants <2 months; ≥50 breaths/min for infants 2-12 months), oxygen saturation (SpO₂) <95%, or chest wall indrawing).

Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up to 180 days (Tarsila Outpatient Study)
Tidsramme: Occurring ≤180 days after birth.

RT-qPCR-confirmed RSV-positive with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Occurring ≤180 days after birth.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
Tidsramme: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:

  • Gestational age at RSVpreF vaccination.
  • Time from RSVpreF vaccination to birth.
  • Time intervals of infant age at illness.
Hospitalization occurring ≤180 days after birth
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tidsramme: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, defined as LRTD plus at least one of the following: respiratory rate ≥70 breaths/min (if <2 months) or ≥60 breaths/min (if ≥2 months); SpO₂ <93%; requirement for high-flow oxygen, non-invasive, or invasive mechanical ventilation; intensive care unit (ICU) admission for >4 hours; or unresponsiveness/loss of consciousness) .

Hospitalization occurring ≤180 days after birth
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
Tidsramme: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, analyzed by:

  • Gestational age at RSVpreF vaccination.
  • Time from RSVpreF vaccination to birth.
  • Time intervals of infant age at illness.
Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up to 180 days by Subgroups (Tarsila Outpatient Study)
Tidsramme: ARI occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by: gestational age at RSVpreF vaccination, time from RSVpreF vaccination to birth, and time intervals of infant age at illness.

ARI occurring ≤180 days after birth

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
Tidsramme: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
Hospitalization occurring ≤180 days after birth
Lower respiratory Tract Disease (LRTD) ICU hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tidsramme: Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization

RT-qPCR-confirmed RSV-positive LRTD ICU hospitalization. ICU admission occuring at any point during the index hospitalization.

Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization
Lower respiratory Tract Disease (LRTD) prolonged hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tidsramme: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD long hospital stay (≥11 days) .

Hospitalization occurring ≤180 days after birth
Lower respiratory Tract Disease (LRTD) in-hospital death among infants aged up to 180 days (Tarsila Inpatient Study)
Tidsramme: Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.

RT-qPCR-confirmed RSV-positive LRTD in-hospital death.

Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.
Hospitalization for lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
Tidsramme: Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by time intervals of infant age at illness.

Hospitalization occurring ≤360 days after birth
Severe lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
Tidsramme: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
Hospitalization occurring ≤180 days after birth
Hospitalization for severe lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
Tidsramme: Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by time intervals of infant age at illness.

Hospitalization occurring ≤360 days after birth
Acute respiratory illness (ARI) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tidsramme: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI hospitalization

Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) hospitalization among infants aged up to 360 days (Tarsila Inpatient Study)
Tidsramme: Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive ARI hospitalization.

Hospitalization occurring ≤360 days after birth
Lower respiratory Tract Disease (LRTD) Hospitalization due to Human Metapneumovirus (HMPV) among infants aged up to 180 days (Tarsila Inpatient Study)
Tidsramme: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed HMPV-positive LRTD hospitalization

Hospitalization occurring ≤180 days after birth
Acute Respiratory Illness (ARI) among infants aged up to 180 days by exploratory subgroups (Tarsila Outpatient Study)
Tidsramme: ARI occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
ARI occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up 360 days (Tarsila Outpatient Study)
Tidsramme: ARI occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by time intervals of infant age at illness.

ARI occurring ≤360 days after birth
Lower respiratory Tract Disease (LRTD) among infants aged up to 180 days (Tarsila Outpatient Study)
Tidsramme: LRTD occurring ≤180 days after birth.

RT-qPCR-confirmed RSV-positive LRTD.

LRTD occurring ≤180 days after birth.
Lower respiratory Tract Disease (LRTD) infants aged up to 360 days (Tarsila Outpatient Study)
Tidsramme: LRTD occurring ≤360 days after birth.

RT-qPCR-confirmed RSV-positive LRTD.

LRTD occurring ≤360 days after birth.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Maicon Falavigna, Inova Medical

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

27. april 2026

Primær fullføring (Antatt)

30. september 2028

Studiet fullført (Antatt)

31. desember 2028

Datoer for studieregistrering

Først innsendt

20. februar 2026

Først innsendt som oppfylte QC-kriteriene

25. februar 2026

Først lagt ut (Faktiske)

3. mars 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CAAE 95166426.7.1001.0008

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .